LeMaitre Vascular (NASDAQ:LMAT) Cut to “Hold” at Wall Street Zen

Wall Street Zen lowered shares of LeMaitre Vascular (NASDAQ:LMAT) from a buy rating to a hold rating in a research report sent to investors on Saturday.

Several other equities analysts have also commented on the company. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Citigroup reissued a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Weiss Ratings lowered LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 30th. Wells Fargo & Company upped their price objective on LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Finally, Citizens Jmp upped their price objective on LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Five equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $112.60.

LeMaitre Vascular Trading Up 2.3%

LeMaitre Vascular stock opened at $103.61 on Friday. The firm’s 50-day moving average is $97.27 and its 200-day moving average is $99.90. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. LeMaitre Vascular has a 1 year low of $79.39 and a 1 year high of $118.01. The company has a market cap of $2.37 billion, a P/E ratio of 38.23, a PEG ratio of 2.81 and a beta of 0.52.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The business had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. During the same quarter in the prior year, the firm earned $0.48 EPS. The company’s revenue for the quarter was up 11.1% compared to the same quarter last year. On average, equities analysts expect that LeMaitre Vascular will post 3 earnings per share for the current year.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Bridget A. Ross sold 5,044 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total value of $560,388.40. Following the sale, the director owned 3,942 shares in the company, valued at approximately $437,956.20. This trade represents a 56.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Trent G. Kamke sold 2,928 shares of LeMaitre Vascular stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $107.00, for a total value of $313,296.00. Following the sale, the insider directly owned 3,749 shares in the company, valued at approximately $401,143. This trade represents a 43.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 54,453 shares of company stock worth $5,906,174. 7.40% of the stock is owned by company insiders.

Institutional Trading of LeMaitre Vascular

Several hedge funds have recently added to or reduced their stakes in LMAT. Illinois Municipal Retirement Fund raised its holdings in shares of LeMaitre Vascular by 1.1% during the 4th quarter. Illinois Municipal Retirement Fund now owns 11,171 shares of the medical instruments supplier’s stock valued at $906,000 after purchasing an additional 123 shares in the last quarter. NewEdge Advisors LLC boosted its holdings in LeMaitre Vascular by 4.6% in the fourth quarter. NewEdge Advisors LLC now owns 3,158 shares of the medical instruments supplier’s stock worth $256,000 after purchasing an additional 139 shares in the last quarter. State of Alaska Department of Revenue boosted its holdings in LeMaitre Vascular by 1.2% in the fourth quarter. State of Alaska Department of Revenue now owns 11,986 shares of the medical instruments supplier’s stock worth $971,000 after purchasing an additional 147 shares in the last quarter. Federated Hermes Inc. increased its position in LeMaitre Vascular by 0.4% during the second quarter. Federated Hermes Inc. now owns 39,659 shares of the medical instruments supplier’s stock worth $3,294,000 after buying an additional 155 shares during the last quarter. Finally, Pictet Asset Management Holding SA increased its position in LeMaitre Vascular by 5.5% during the first quarter. Pictet Asset Management Holding SA now owns 3,259 shares of the medical instruments supplier’s stock worth $356,000 after buying an additional 169 shares during the last quarter. Institutional investors own 84.64% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.